Edition:
United States

Health News

GSK sees breakthrough in shingles vaccine output in 2024

GlaxoSmithKline said further growth from its shingles vaccine, which has boosted earnings, would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a step change in production.

Health Reform Watch